Ory Jesse, Blankstein Udi, Gonzalez Daniel C, Sathe Aditya A, White Joshua T, Delgado Carlos, Reynolds John, Jarvi Keith, Ramasamy Ranjith
Department of Urology, Miller School of Medicine, University of Miami, Miami, FL, USA.
Department of Surgery, Division of Urology, University of Toronto, Toronto, ON, Canada.
BJUI Compass. 2021 Sep;2(5):306-321. doi: 10.1002/bco2.77. Epub 2021 Feb 23.
To perform a systematic review on the effects of testicular sparing surgery (TSS) on the oncological, functional, and hormonal outcomes of adults with testicular tumors.
A literature search was performed after PROSPERO registration (CRD42020200842) and reported in compliance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methods. We conducted a systematic search of Medline (Ovid), Embase, Cochrane CENTRAL, CINAHL, Scopus, Web of Science, ClinicalTrials.gov, and the WHO/ICTRP from inception to November 20, 2020. Manuscripts and published abstracts were included if they involved testis-sparing surgery (TSS) and contained data on any outcomes related to fertility, hormonal parameters, or oncological control, or if they evaluated surgical technique.
Our initial search yielded 3,370 manuscripts, with 269 of these screened for full-text eligibility. After our exclusion criteria were applied, 32 studies were included in the final analysis. Oncological outcomes were obtained from 12 studies (average follow-up 57.8 months), functional data from 26 studies (average follow-up 49.6 months), fertility information from 10 studies (average follow-up 55.8 months), and data on nonpalpable tumors from 11 studies (average follow-up 32.1 months). Oncological control appears to be excellent in studies that reported these outcomes. Presence of germ cell neoplasia in situ was controlled with adjuvant radiation in nearly all cases. Functional outcomes are also promising, as development of primary and compensated hypogonadism was rare. Semen parameters are poor preoperatively among men with benign and malignant testis tumors, with occasional decline after TSS. Frozen section analysis at the time of surgery appears to be very reliable, and the majority of nonpalpable tumors appear to be benign.
TSS is a safe and efficacious technique with regards to oncological control and postoperative hormonal function based on retrospective, noncontrolled studies. TSS avoids unnecessary removal of benign testicular tissue, and should be given serious consideration in cases of nonpalpable, small tumors under 2 cm. In cases of malignancy, TSS can safely avoid anorchia in men with bilateral tumors and in men with solitary testicles. The use of the operating microscope, while theoretically promising, does not necessarily lead to better outcomes, however data are limited.
对保留睾丸手术(TSS)对成年睾丸肿瘤患者的肿瘤学、功能和激素方面结局的影响进行系统评价。
在PROSPERO注册(CRD42020200842)后进行文献检索,并按照系统评价和Meta分析的首选报告项目(PRISMA)方法进行报告。我们对Medline(Ovid)、Embase、Cochrane CENTRAL、CINAHL、Scopus、Web of Science、ClinicalTrials.gov以及WHO/ICTRP进行了从创刊到2020年11月20日的系统检索。如果手稿和已发表的摘要涉及保留睾丸手术(TSS)且包含与生育、激素参数或肿瘤控制相关的任何结局的数据,或者评估了手术技术,则纳入研究。
我们最初的检索产生了3370篇手稿,其中269篇经过全文筛选是否符合纳入标准。应用我们的排除标准后,最终分析纳入了32项研究。肿瘤学结局来自12项研究(平均随访57.8个月),功能数据来自26项研究(平均随访49.6个月),生育信息来自10项研究(平均随访55.8个月),不可触及肿瘤的数据来自11项研究(平均随访32.1个月)。在报告了这些结局的研究中,肿瘤控制似乎良好。几乎所有病例中,原位生殖细胞肿瘤均通过辅助放疗得到控制。功能结局也很有前景,因为原发性和代偿性性腺功能减退的发生很少见。良性和恶性睾丸肿瘤男性术前精液参数较差,保留睾丸手术后偶尔会下降。手术时的冰冻切片分析似乎非常可靠,大多数不可触及的肿瘤似乎是良性的。
基于回顾性、非对照研究,保留睾丸手术在肿瘤控制和术后激素功能方面是一种安全有效的技术。保留睾丸手术避免了不必要地切除良性睾丸组织,对于2cm以下不可触及的小肿瘤病例应予以认真考虑。对于恶性肿瘤病例,保留睾丸手术可以安全地避免双侧肿瘤男性和单睾丸男性出现无睾症。手术显微镜的使用虽然理论上有前景,但不一定能带来更好的结局,不过数据有限。